MOTS-c is a 16-amino-acid mitochondrial-derived peptide. Mechanism, half-life, the Lee/Cohen corpus, the r/Peptides anaphylaxis signal, and where the evidence still thins. RUO research reference, not medical advice.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
Disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full FTC disclosure on the About page.
MOTS-c — Mitochondrial Open reading frame of the Twelve S rRNA type-c — is a 16-amino-acid peptide encoded inside the mitochondrial genome rather than the nuclear genome. That detail is not trivia. It places MOTS-c in a small class of "mitochondrial-derived peptides" (MDPs) that the cell produces from mitochondrial DNA, secretes systemically, and uses as a metabolic signal between tissues.
Category: metabolic and mitochondrial research compound. Same conversation as the GLP-1 class on the metabolic side and as NAD+ precursors on the mitochondrial side, but a different mechanism than either.
It is not a GH-axis peptide. It is not a recovery peptide. It does not act on the HPG axis. The single-line summary is "endogenous metabolic signal that the literature places upstream of AMPK in skeletal muscle."
The foundational author here is Pinchas Cohen at USC, with Changhan David Lee as the lead postdoc on the original characterization. Lee, Cohen, and colleagues published the first description of MOTS-c as a bioactive mitochondrial-derived peptide in 2015 in Cell Metabolism. That paper is the entry point.
The proposed mechanism, in plain English: MOTS-c circulates and signals into skeletal muscle, where it activates AMPK — AMP-activated protein kinase, the cellular energy sensor that gets switched on when the AMP/ATP ratio rises (i.e., when the cell is energy-stressed). Activating AMPK shifts metabolism toward glucose uptake, fatty-acid oxidation, and away from anabolic pathways. It is the same enzyme metformin is generally credited with activating, by a different upstream route.
Downstream effects in animal work include improved insulin sensitivity, resistance to diet-induced obesity, and — in older mice — restored exercise capacity. The "exercise mimetic" framing comes from this corpus, and operators should treat that framing as a researcher's hypothesis, not a settled mechanism.
One technical term worth unpacking: AMPK is a heterotrimeric kinase, meaning it has three subunits, and it sits at a metabolic branch point. When AMPK is on, the cell prioritizes catabolism — burning fuel — over anabolism. This is why an AMPK-activating signal is interesting in a metabolic and longevity conversation but not interesting in a hypertrophy conversation. They pull in opposite directions.
Half-life. The published pharmacokinetic data on synthetic MOTS-c in humans is thin. Animal work places systemic clearance in the short range. Operators should treat the half-life as poorly characterized and interpret community dosing schedules accordingly — most reflect inference from the animal corpus, not human PK.
Route. Subcutaneous injection is the dominant administered route in research contexts. Intraperitoneal injection appears in mouse studies. Oral preparations exist in vendor markets but the published support for oral bioavailability is thin.
The Compound's Tier framework: Tier 1 is large human RCTs. Tier 2 is smaller human studies or strong animal work in disease-relevant models. Tier 3 is mechanistic and preclinical. Tier 4 is hypothesis and N=1.
For MOTS-c:
Search "MOTS-c" on PubMed for the substantive corpus. The Lee/Cohen group output is the spine.
The single operator-grade signal worth knowing about MOTS-c does not come from the literature. It comes from the r/Peptides community.
Anaphylaxis reports. Multiple users on r/Peptides over the past several years have documented systemic allergic reactions on MOTS-c administration that escalated to anaphylaxis-pattern presentations — full-body urticaria, throat tightness, in a small number of reported cases requiring epinephrine. This is not a bro-science noise signal. It is a structurally different report from the typical PIP or GI side-effect chatter that surrounds most peptides.
The mechanism is not established. Hypotheses in the community discussion include excipient or contaminant reactions, true peptide hypersensitivity, and lot-specific issues at particular vendors. None of those hypotheses is settled.
What is the operator-level read: MOTS-c sits in a small group of research peptides where the community-reported safety signal is qualitatively different from the rest of the stack. Recovery peptides like BPC-157 and TB-500 produce noisy site-reaction chatter. MOTS-c produces a small but persistent stream of systemic-reaction reports. That asymmetry is worth knowing before any decision-making conversation.
Beyond that signal, community-reported subjective effects on energy, exercise capacity, and glycemic response are noisy, mixed, and not strong enough to draw an N=1 pattern from at the level of the public corpus.
A short list, because honesty about the gap is the point of this page.
The Compound covers MOTS-c in the metabolic-axis arc of the briefing, alongside the GLP-1 class, AOD-9604, and the NAD+ precursor conversation. The throughline is metabolic signaling and body composition — the territory most operator stacks are pointed at.
If your reason for reading this page is a GLP-1 or tirzepatide protocol and you're trying to think about what else converges on the same metabolic real estate, the lead magnet below is the more direct read.
If your reason is mitochondrial-and-longevity framing, MOTS-c is one piece. The NAD+ precursor and rapamycin conversations are the other pieces of that map. We work through the synthesis in the weekly briefing.
Related issues: Issue 1 — the metabolic-axis primer.
Related compounds: Semaglutide, tirzepatide, retatrutide, NAD+ (and precursors NMN/NR), MK-677.
If you came here from a GLP-1 protocol, the more directly useful read is the muscle-preservation guide. It is the operator-grade summary of what the literature shows about losing fat without losing lean mass on the GLP-1 class — which is the question MOTS-c orbits.
Get the guide: thecompoundbrief.com/glp1-muscle-preservation
The Sunday briefing on peptides for founder-operators. One email. What's new in the literature, what survived peer review, what moved up or down on the operator stack, and the cited summaries that fit better behind the email gate than on a public page like this one.
Subscribe at thecompoundbrief.com.
For research use only. This page is a literature reference for research purposes. Nothing on it is medical advice, and nothing on it is a recommendation to administer, prescribe, or self-administer any compound discussed.
FDA disclaimer. None of the statements on this page have been evaluated by the U.S. Food and Drug Administration. MOTS-c is not approved for human use in the United States. Research compounds are not intended for human consumption.
FTC disclosure. The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Editorial coverage on this site is independent of vendor selection. Full disclosure on the About page.
No medical advice. Consult a qualified medical professional before making any decisions about your health, medications, or supplementation.
What survives Phase 3, what survives the field. The 39% question, decoded.
Download the PDF →